share_log

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

compass therapeutics将参加派杰投资第36届年度医疗会议
GlobeNewswire ·  12/02 05:00

BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper Sandler 36th Annual Healthcare Conference taking place in New York City, NY December 3-5, 2024.

波士顿,2024年12月02日(环球新闻社)- compass therapeutics 公司(纳斯达克股票代码:cmpx)一家专注于肿瘤治疗的临床阶段生物制药公司,正在开发用于治疗多种人类疾病的专有抗体疗法,今天宣布公司将参加于2024年12月3-5日在纽约举行的派杰投资第36届健康医疗大会。

Presentation details
Date: Wednesday, December 4, 2024
Time: 9:50-10:10 AM EST
Webcast Link:

演讲详情
日期:2024年12月4日星期三
时间:美国东部时间上午9:50-10:10
网络广播链接:

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass' Events page.

虚拟/重播可用性:公司演示将存档在compass活动页面上,为期90天。

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at .

关于compass therapeutics
Compass Therapeutics是一家临床阶段的生物制药公司,致力于开发基于专利抗体的治疗多种人类疾病的专有治疗产品。Compass的科学重点是在血管生成、免疫系统和肿瘤生长之间的关系。该公司的新颖产品候选药物流水线旨在针对多个关键的生物途径,这些途径对于有效的抗肿瘤反应非常重要。这些包括通过靶向血管生成的药物对微血管的调节,通过在肿瘤微环境中的效应细胞上激活剂诱导强效免疫反应,并减轻瘤细胞用来逃避免疫监视的免疫抑制机制。Compass计划通过临床发展将其产品候选药物作为独立疗法和与基于支持性临床和非临床数据的专有流水线抗体组合使用。该公司成立于2014年,总部位于马萨诸塞州波士顿。有关更多信息,请访问Compass Therapeutics网站。

Investor Contact
ir@compasstherapeutics.com

投资者联系人
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Senior Manager of Communications
media@compasstherapeutics.com
617-500-8099

媒体联系
安娜·吉福德,通信-半导体高级经理
media@compasstherapeutics.com
617-500-8099


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发